Imetelstat (a telomerase antagonist) exerts off target effects on the cytoskeleton

International Journal of Oncology

Volumn 42, Issue 5, 2013, Pages 1709-1715

  Mender, Ilgen ^a,f   Senturk, Serif ^b   Ozgunes, Nuriman ^a   Can Akcali, K ^b   Kletsas, Dimitris ^d   Gryaznov, Sergei ^e   Can, Alp ^c   Shay, Jerry W ^f,g   Dikmen, Z Gunnur ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b BILKENT UNIVERSITY   (Turkey)

^c ANKARA UNIVERSITY   (Turkey)

^d INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^e GERON CORPORATION   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Cell adhesion; E cadherin; GRN163L; Matrix metalloproteinase 2; Non small cell lung cancer

Indexed keywords

ACTIN; ALPHA ACTININ; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLOPHILIN A; F ACTIN; GELATINASE A; IMETELSTAT; MESSENGER RNA; TELOMERASE; TUBULIN; UVOMORULIN;

ARTICLE; CELL ADHESION; CELL PROLIFERATION; CYTOSKELETON; DOWN REGULATION; DRUG EFFICACY; ENZYME ACTIVITY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; CYTOSKELETON; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; MICE; NIACINAMIDE; TELOMERASE; TELOMERE HOMEOSTASIS;

EID: 84875984655     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1865     Document Type: Article

References (21)

1. Dempke WC, Suto T and Reck M: Targeted therapies for non-small cell lung cancer. Lung Cancer 67: 257-274, 2010.
2. Tassinari D, Scarpi E, Sartori S, Tamburini E, Santelmo C, Tombesi P and Lazzari-Agli L: Second-line treatments in non-small cell lung cancer. A systematic review of literature and metaanalysis of randomized clinical trials. Chest 135: 1596-1609, 2009.
3. Blackburn EH: Switching and signaling at the telomere. Cell 106: 661-673, 2001. (Pubitemid 32900658)
4. Greider CW and Blackburn EH: Telomeres, telomerase and cancer. Sci Am 274: 92-97, 1996.
5. Hiyama E and Hiyama K: Telomere and telomerase in stem cells. Br J Cancer 96: 1020-1024, 2007. (Pubitemid 46608315)
6. Collins K and Mitchell JR: Telomerase in the human organism. Oncogene 21: 564-579, 2002. (Pubitemid 34146256)
7. Blasco MA: Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet 6: 611-622, 2005. (Pubitemid 41044298)
8. Wai LK: Telomeres, telomerase and tumorigenesis - a review. Med Gen Med 6: 19, 2004.
9. Shay JW and Wright WE: Telomerase: a target for cancer therapeutics. Cancer Cell 2: 257-265, 2002. (Pubitemid 41043959)
10. Harley CB: Telomerase and cancer therapeutics. Nat Rev Cancer 8: 167-179, 2008. (Pubitemid 351305939)
11. Herbert BS, Gellert GC, Hochreiter A, et al: Lipid modification of GRN163, an N3′→P5′ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene 24: 5262-5268, 2005. (Pubitemid 41192444)
12. Gryaznov SM: Oligonucleotide N3′→P5′ phosphoramidates and thio-phoshoramidates as potential therapeutic agents. Chem Biodivers 7: 477-493, 2010.
13. Dikmen ZG, Gellert GC, Jackson S, et al: In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res 65: 7866-7873, 2005. (Pubitemid 41297263)
14. Jackson SR, Zhu CH, Paulson V, et al: Antiadhesive effects of GRN163L - an oligonucleotide N3′→P5′ thio-phosphoramidate targeting telomerase. Cancer Res 67: 1121-1129, 2007.
15. Svitkina T: Imaging cytoskeleton components by electron microscopy. Methods Mol Biol 586: 187-206, 2009.
16. Pećina-Slaus N: Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int 3: 17, 2003.
17. Qian Q, Wang Q, Zhan P, Peng L, Wei SZ, Shi Y and Song Y: The role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: a systematic review with meta-analysis. Cancer Invest 28: 661-669, 2010.
18. Goldblatt EM, Gentry ER, Fox MJ, Gryaznov SM, Shen C and Herbert BS: The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel. Mol Cancer Ther 8: 2027-2035, 2009.
19. Shin IJ, Ahn YT, Kim Y, Kim JM and An WG: Actin disruption agents induce phosphorylation of histone H2AX in human breast adenocarcinoma MCF-7 cells. Oncol Rep 25: 1313-1319, 2011.
20. Perez EA: Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther 8: 2086-2095, 2009.
21. Hojilla CV, Mohammed FF and Khokha R: Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 89: 1817-1821, 2003. (Pubitemid 37533251)